Dupilumab Faces Trial in Chronic Hives - Top-Institutions - MDSpire

Dupilumab Faces Trial in Chronic Hives

Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.

  • By

  • Kathryn Wighton

  • March 12, 2026

  • 5 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Allergy and Immunology
    • Clinical Trials
    • Immunotherapy

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Allergy and Immunology
    • Dermatology
    • Clinical Research

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Allergy and Immunology
    • Clinical Immunology
    • Translational Research

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Allergy and Immunology
    • Dermatology
    • Clinical Trials

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Allergy and Immunology
    • Clinical Research
    • Immunotherapy

Original Source(s)

Dupilumab Faces Trial in Chronic Hives

  • by Kathryn Wighton

  • March 12, 2026

Related Content

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

What Parents Need to Know About Moles in Children